Peter Feldschreiber is dually qualified as a barrister and physician (B.Sc. MB.BS Kings College Hospital Medical School, Fellow Faculty of Pharmaceutical Medicine Royal College of Physicians). He specialises and advises in all aspects of medical and healthcare law including healthcare products liability, pharmaceutical and medical devices regulatory law, clinical negligence, personal injury and medically related employment litigation. He has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Commission on Human Medicines and the Committee on Safety of Devices, Medicines, and Healthcare Products Regulatory Agency, Department of Health. In particular he is regularly consulted by US healthcare product companies on all aspects of European regulatory law.
He is retained counsel to a number of solicitors and has experience of international litigation regarding drug induced injury.
Peter has lectured and written extensively on pharmaceutical law and regulation; he is General Editor of the Law and Regulation of Medicines, Oxford University Press 2008.
Peter is to be Consultant Editor for the section on Medicinal Products and Drugs in the Fifth Edition of Halsbury's Laws of England.
Quotes in the Directories and elsewhere:
Peter is a recommended leading junior whose "unique experience as a physician, pharma regulator and barrister gives him an encyclopaedic knowledge of pharma-related issues". Legal 500 2012.
‘Medical qualifications, coupled with his in-depth knowledge of the pharmaceutical industry, give him a unique perspective on life sciences product liability cases' Legal 500 2011
‘Sought after for his extensive scientific knowledge in pharmaceutical cases’ Chambers 2010
‘Frequently instructed in drug induced injury cases’ Legal 500 2010
‘Up and coming individual’ Chambers 2009
Peter is listed in the third edition of the Best Lawyers in the United Kingdom.
‘I shall expect when I sit in Court to see not only the barristers and solicitors but the clients sitting with a copy of Feldschreiber open in front of them. But more important, I suspect that the regulator and the drug developer too will keep this book close at hand.’ Mr Justice Burton, Foreword to the Law and Regulation of Medicines.
Product liability and regulatory law and procedure:
Casework since approximately September 2008 includes:
Vigabatrin litigation: drug induced visual defects caused by anti-epileptic medication.
Foetal anti-convulsant litigation: teratogenetic effects of Epilim
Seroquel litigation: US class action for injuries caused by anti-psychotic medication
Implantable cardiac catheters: Judicial review and regulatory action to remove authorisation of cardiac ablation catheters
Unlicensed medicines: advice on regulation of cosmetic/medicinal therapies for healing scars after plastic surgery
Biosimilar medicines: advice on intellectual property and regulatory data exclusivity
Nuclear test Veterans litigation: Group action re damage caused by ionising radiation from nuclear weapons testing in the South Pacific during tests organised by Ministry of Defence.
Porton Down Clinical trial litigation
Pulmonary Hypertension drugs arbitration (United States)